Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -19.01
- Piotroski Score 3.00
- Grade Hold
- Symbol (ATNF)
- Company 180 Life Sciences Corp.
- Price $2.28
- Changes Percentage (-2.59%)
- Change -$0.06
- Day Low $2.21
- Day High $2.45
- Year High $17.75
1180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials that are man-made derivatives of CBD; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/26/2025
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$30.12
- Trailing P/E Ratio -0.05
- Forward P/E Ratio -0.05
- P/E Growth -0.05
- Net Income $-19,935,112
Income Statement
Quarterly
Annual
Latest News of ATNF
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
ATNF Stock Price | 180 Life Sciences Corp. Stock Quote (U.S.: Nasdaq) | MarketWatch
180 Life Sciences Corp. is a biotech company focusing on developing drugs for inflammatory diseases, fibrosis, and pain. Founded in 2016, it collaborates with experts from Oxford, Hebrew, and Stanford...
By MarketWatch | 3 months ago
